| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS44015550 | HTLV-1 | ENSG00000203747.13 | protein_coding | FCGR3A | No | No | 2214 | P08637 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | FCGR3A |
|---|---|
| DrugBank ID | DB00092 |
| Drug Name | Alefacept |
| Target ID | BE0002097 |
| UniProt ID | P08637 |
| Regulation Type | |
| PubMed IDs | 17139284; 17016423; 11970990; 12795239 |
| Citations | Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@da Silva AJ, Brickelmaier M, Majeau GR, Li Z, Su L, Hsu YM, Hochman PS: Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J Immunol. 2002 May 1;168(9):4462-71.@@Vaishnaw AK, TenHoor CN: Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. J Pharmacokinet Pharmacodyn. 2002 Dec;29(5-6):415-26. |
| Groups | Approved; Investigational; Withdrawn |
| Direct Classification | Peptides |
| SMILES | |
| Pathways | |
| PharmGKB | PA164748040 |
| ChEMBL | CHEMBL1201571 |
